ABSTRACT: Human leukocyte antigen (HLA) class I downregulation, a frequent phenomenon observed in a variety of human tumors, favors tumor immune escape from T-lymphocyte recognition. However, it is not known whether a particular HLA class I allele is lost more frequently than others. To address this question we analyzed HLA class I expression in tumor tissues derived from 300 patients diagnosed as having breast, colorectal, or laryngeal carcinomas. Cryostatic tumor sections and a broad panel of anti-HLA class I monoclonal antibodies were used. We found that the HLA-B44 allele was lost more frequently than other HLA class I alleles, and that the difference was not related with changes in HLA-B44 allele frequencies between patients and controls. In addition, we observed that 35% of the HLA-B44 negative tumors presented HLA haplotype loss associated with loss of heterozygosity. These tests were performed on DNA samples obtained from microdissected tumor tissues. The results seem to indicate that HLA class I allelic losses are not randomly distributed during tumor development but that some HLA class I alleles, and HLA-B44 in particular, are more frequently downregulated and may play an important role in immune escape mechanisms. Human Immunology 64, 941-950 (2003).
INTRODUCTION
Human tumors derived from human leukocyte antigen (HLA) class I positive epithelia totally or partially lose HLA class I antigens during tumor development [1] [2] [3] . This finding has been interpreted as a consequence of immune selection of HLA class I deficient tumor cell clones by a highly selective antitumor immune response mediated by cytotoxic T lymphocytes and directed against tumor-specific antigens [4 -6] . These variant clones can escape specific T-cell responses and acquire new properties that allow them to invade and metastasize. Evidence obtained recently in experimental tumor systems supports this hypothesis [7] .
Altered HLA class I tumor phenotypes can be classified into several major groups depending on the mechanism and the number of alleles lost: HLA total loss (phenotype I), HLA haplotype loss (phenotype II), HLA-A or -B locus loss (phenotype III), HLA allelic losses (phenotype IV), compound phenotype (phenotype V), unresponsiveness to interferons (phenotype VI), and expression of HLA-E in HLA class Ia deficient tumors (phenotype VII) [3, 8, 9] . It is not known, however, whether a particular HLA class I allele is lost more frequently than others. To address this problem we analyzed the frequency of HLA allelic losses in those HLA specificities that could be defined with the panel of HLA class I monoclonal antibodies (mAbs) from the HLA and Cancer Component of the 12th International Histocompatibility Workshop (IHW) [10] .
We present here our analysis of HLA class I antigen expression in tumor tissues derived from 300 patients diagnosed as having laryngeal, colorectal, or breast carcinomas, and report the frequency of individual HLA class I allelic losses as defined by immunohistologic techniques.
MATERIALS AND METHODS Patients
Three hundred patients diagnosed as having laryngeal (77), colon (93), or breast (130) carcinoma were selected for this study. Samples of tumor tissues were provided by the Departments of Otolaryngology, Surgery, and Obstetrics and Gynecology at the Hospital Universitario Virgen de las Nieves in Granada, Spain. As a control population we used the data reported by Arnaiz-Villena et al. [11] on HLA frequencies obtained in 176 healthy adults of the same ethnic group. All patients and controls belonged to the Caucasoid ethnic group.
Tumor Tissue Samples
The central portion of each piece of tumor was divided into two pieces, one of which was used for conventional histopathologic studies. The other, used for cryostatic sections, was snap-frozen in isopentane cooled with liquid nitrogen and stored in liquid nitrogen until sectioned for study. The tumor tissues were processed according to procedures described previously [12] . Some details about types of samples are provided in Table 1 .
Immunohistologic Staining
The HLA class I tumor phenotype was defined by using immunohistologic techniques on cryostatic tumor sections with a biotin-streptavidin amplified (B-SA) detection system (supersensitive Multilink-HRP/DAB; BioGenex, San Ramon, CA, USA). Technical details and the system used to score the results were described previously [13] . The reactivity of mAbs with stromal and infiltrating cells was always used as an internal control, and positive staining of both was required for a tumor to be considered HLA negative. Although we are aware that infiltrating cells and tumoral cells may differ in intensity, tumor cells with positive reactivity with these mAbs did not reveal evident differences in intensity and pattern of reactivity between epithelial and infiltrating cells (see Figure 1 for examples of reactivity).
We used serologic HLA specificities to compare HLA expression in tumor tissues and peripheral blood lymphocytes (PBL).
Monoclonal Antibodies
The panel of anti-HLA class I mAbs used in this study was selected at the HLA & Cancer Component of the 12th IHW (for details see Garrido et al. [10] ). Confirmation of whether these antibodies work properly requires HLA typing of PBL from the patients from whom the tumor was obtained. Reactivity with the different mAbs was graded in accordance with the recommendations of the 12th IHW [10] as: negative (Ͻ25% cells stained), heterogeneous (25%-75% cells stained), or positive (Ͼ75% cells stained).
HLA Typing of Peripheral Blood Lymphocytes
Peripheral blood lymphocytes were isolated from cancer patients and HLA typed in our laboratory using the The procedures for these techniques were recently described in detail [12] . Normal autologous cells from stroma-surrounded tumor nests were always used as a control. SSO HLA typing was performed using Dynal Reli SSO HLA-A and HLA-B kit (Dynal, Oslo, Norway).
Typing was done with DNA obtained from microdissected stroma and tumor cells.
Loss of Heterozygosity Analysis
DNA obtained from tissue specimens was studied with eight short tandem repeat (STR) markers mapping chromosome 6; six of them (D6s311, D6s291, D6s273, D6s265, D6s105, and D6s276) were previously described by Ramal et al. [14] . In this work we used two additional markers next to HLA-B loci: C.1.2.c and C.1.2.5 [15] . Both of them (forward primers) were tagged with a blue fluorescent label (FAM) and combined in the same tube, using 1-4 pmol of each primer (forward and reverse) because of their different size range. PCR, electrophoresis, and data analyses were done as described previously by Ramal et al. [16] . Loss of heterozygosity (LOH) was recorded when the signal of one allele was reduced by Ͼ 25% in the tumor sample compared with the control stroma sample. Haplotype loss was recorded when a tumor manifested allelic reduction in three or more STR markers.
Statistical Analysis
For statistical comparisons we used a control population of 176 healthy adults of the same ethnic group (see Arnaiz-Villena et al. [11] ). In tumor samples, allele frequencies were compared with the chi-squared test or with Fisher's exact test when the expected value was less than 5. Values less than 0.05 were regarded as significant. When we compared allele or haplotype frequencies between controls and patients, Bonferroni correction was used by multiplying the probability value by the number of comparisons to obtain a corrected p value. All data were analyzed with SPSS (Chicago, IL, USA) and Epi Info (Centers for Disease Control, Atlanta, GA, USA) software.
RESULTS

Immunohistologic Analysis
We used immunohistologic techniques to study cryostatic sections of tissues from a total of 300 patients diagnosed as having colon, laryngeal, or breast carcinoma. Studies with W6/32 and ␤ 2 -microglobulin mAbs detected 214 positive and 86 negative tumors; these latter 86 samples included those with heterogeneous staining (25%-75% positive cells). The positive cases were then studied with anti-locus A and B mAbs, which detected 14 HLA-A negative, 26 HLA-B negative, and 17 A-and B-negative tumors ( Figure 2 ).
The group of samples positive for HLA-ABC, ␤ 2 -microglobulin, locus A, or locus B (n ϭ 157) were then tested with anti-HLA mAbs, which defined the set of alleles that were theoretically expected to be present in the cells on the basis of HLA PBL typing. We found HLA allelic losses in 82 of 157 patients (27%) (Figure 2 ), as judged from the absence of reactivity of tumor cells with the corresponding mAb. Some tumors presented more than one allelic loss ( Table 2 ). In the remaining patients (n ϭ 75) it was not possible to demonstrate HLA allelic losses. It should be remembered, however, that mAbs against some specificities present in these patients were not available. In all, HLA class I alterations (including total, locus, and allelic losses) were observed in 225 (75%) tumors (Figure 2 ).
Analysis of HLA Allele Frequency in Patients
HLA-A and -B specificities in cancer patients were compared with a population of 176 healthy adults of the same ethnic group. No HLA specificity differed significantly in frequency between patients and controls when p values were corrected for the number of specificities and alleles tested.
We also compared the frequency of haplotypes that exhibited linkage disequilibrium in our population, including the A29-B44 haplotype [11] . No differences were found between the two groups. Statistical analysis considering the type of tumor failed to demonstrate statistically significant differences between the two groups.
Analysis of the Frequency of HLA Class I Allele Losses in Tumor Samples
To prove that the population analyzed was not biased, we also compared HLA class I allele frequencies with tumors that were HLA-ABC or locus negative. No differences were found. HLA class I allele expression was studied in 157 tumors positive for HLA-ABC, ␤ 2 -microglobulin, locus A, and locus B.
In these 157 tumors, HLA-B44 was the allele most frequently lost (30 of 42 cases, 71.4%, Figure 3 ). This allele was significantly downregulated (p Ͻ 0.01, Figure   FIGURE 2 Method for classifying patients whose tumor demonstrated human leukocyte antigen (HLA) alterations. In the first stage, patients were classified as positive or negative-heterogeneous on the basis of W6/32 and anti-␤ 2 -microglobulin reactivity. In the second stage, patients were subdivided using anti-HLA-A or -B locus-specific monoclonal antibodies (mAbs). In the third stage, tumors were subdivided according to their reactivity with anti-HLA allelic mAbs. Patients were considered to have alterations when there was no staining or when staining was heterogeneous, i.e., with 25%-75% negative cells. 
HLA-B44 negative tumors without LOH in chromosome 6
White boxes indicate positive reaction with the corresponding anti-HLA class I mAb. Gray boxes indicate negative reaction. No boxes indicate absence of anti-HLA class I mAb. For details of the anti-HLA allelic antibodies used, see Cabrera et al. [13] . HLA haplotype loss is revealed in tumors C1 84, 91, CO13, 67, 69, and 101. In some tumors HLA haplotype could not be determined due to LOH Ͻ50% by STR analysis (N † ). ‡ CO69 was homozygous for A24.
Abbreviations: H ϭ homozygous; HLA ϭ human leukocyte antigen; L ϭ LOH equal to or greater than 0.25% reduction compared with the autologous control; LOH ϭ loss of heterozygosity; MIN ϭ microsatellite instability; N ϭ normal, absence of alterations; ND ϭ not determined; SSO ϭ sequence-specific oligonucleotide.
3) in comparison to the most frequent alleles in the population (HLA-A2, A3, A24, A30, B7, and B18). For example, HLA-A2, the most frequent allele in our sample, was downregulated only in 11 of 73 tumors. Alleles that did not differ significantly in comparison to the HLA-B44 allele ( Figure 3) were those found less frequently (HLA-A23, A31, B8, B45, and B13), which were detected in fewer than 15 patients. When we compared the HLA-A and HLA-B alleles, we found that allelic losses were more frequent in HLA-B (47%) than in HLA-A alleles (17%). In the HLA-B group, alleles with Bw4 specificity were lost more frequently (43%) than HLA-Bw6 (22%); this was thought to reflect the fact that the HLA-B44 allele is Bw4.
Because of the low frequency of each allele in each tissue, statistically significant differences were found only when the data for all tissues (laryngeal, colon, and breast) were pooled. However, although no statistically significant relationship could be found, the HLA-B44 allele was also lost more frequently than the other alleles in all three tumor tissues (data not shown).
LOH Analysis in HLA-B44 Negative Colorectal and Laryngeal Carcinomas
To determine whether HLA-B44 negative tumors had lost HLA-B44 expression because of a haplotype deletion (phenotype II) or because of selective allele loss (phenotype IV, Table 2 ), we performed microsatellite studies of chromosome 6 in 26 samples (16 colon adenocarcinomas and 10 laryngeal carcinomas) chosen from the 30 tumors that were found with immunohistologic techniques to be negative for the HLA-B44 allele. Four samples of breast carcinoma were not studied with this technique due to difficulties with the microdissection procedure. Table 2 illustrates the results obtained with markers that mapped the HLA class I region. Nine tumors (4 laryngeal and 5 colon carcinomas) of the 26 tumors studied (35%) revealed LOH for the HLA class I region (phenotype II, Table 2, Figure 4 ). Genomic typing was done with SSO using DNA from microdissected tumor tissue to define the deleted haplotype. Table 2 illustrates that the haplotype lost most often was HLA-A*29-B*44 (5 samples), whereas the HLA-A*02-B*44 haplotype was lost in only 1 sample. Therefore, we were unable to determine which haplotype had been lost in two samples with LOH scores of 0.6 (CL72) and 0.7 (CL73), because the SSO typing technique detected alterations only when STR allelic loss detected with microsatellite analysis was manifested as a reduction in signal intensity of 50% or more.
In 16 tumors (6 laryngeal carcinomas and 10 colon carcinomas) we found downregulation of HLA-B44 without LOH (Table 2) . Therefore HLA-B44 expression had probably been lost selectively in these tumors (phenotype IV). One tumor (CO-1) exhibited microsatellite instability (MIN) and could not be analyzed.
DISCUSSION
The aim of this study was to determine whether the loss of HLA class I expression affects locus A and locus B alleles to the same or different degrees in neoplasms of the colon, breast, and larynx. Tests with polymorphic mAbs in histologic sections demonstrated that HLA-A and HLA-B allelic losses were not randomly distributed, but that the process of oncogenesis differentially affected the expression of different HLA class I alleles. For some alleles, such as HLA-A2 (the most frequent in the Caucasoid population), expression is conserved in most tumors, as also occurs for HLA-A30 and HLA-A24. In contrast, HLA-B44 (the most frequent allele in the HLA-B locus), exhibits the opposite behavior, disappearing from the surface of tumor cells in a large percentage of cases (71.4%). For some alleles loss of expression was not statistically significant in comparison to HLA-B44 (e.g., A23, A31, B8, B45, and B13), but we believe this is largely due to the low frequency of these alleles in Caucasoids. Because no specific mAbs are available for immunohistologic testing of all HLA class I alleles, we were unable, with this technique, to determine whether HLA-B44 negative tumors had lost HLA-B44 expression because of LOH in the 6p21.3 region (phenotype II) or because of selective downregulation of HLA-B44 (phenotype IV). As an alternative we analyzed LOH with microsatellite markers for the HLA class I region. Using this technique, we were able to establish that 9 of 26 HLA-B44 negative tumors belonged to phenotype II, and that in this group the haplotype that was deleted most often was HLA-A29-B44. Genomic typing with SSO confirmed this finding. Apparently the HLA-B44 allele is lost most frequently via a selective mechanism (16/26 tumors, see Table 2 ). This was seen more clearly when LOH was studied in samples that contained both HLA-B44 negative and HLA-B44 positive tumors. For example, a recent study of laryngeal tumors [17] found that out of 7 tumors with phenotype IV, 6 were HLA-B44 negative. Unpublished work in our laboratory with colorectal carcinoma lesions revealed similar results, namely, that most HLA-B44 negative tumors belong to phenotype IV.
The mechanism that leads to the high frequency of HLA-B44 allelic losses are unknown. One possibility is a structural lesion (mutation) in the HLA-B44 gene that affects the open reading frame or intron regions, thus altering the process of mRNA splicing, as has been reported for the HLA-A2 gene [18, 19] . Activation of certain oncogenes may block transcription of the B locus [20] , and in some cases this may in turn affect only the HLA-B44 allele. In the present study HLA-B locus antigens tended to be more defective than HLA-A locus antigens, a finding also reported by others [21] .
The peptide processing, transport, and binding machinery in the cleft of HLA class I molecules regulates their level of expression and turnover on the cell membrane in a precise manner. HLA class I alleles differ in their requirements for antigen processing components; for example, tumors frequently exhibit alterations in the levels of TAP1-2, LMP2, LMP7, or tapasin expression [22] [23] [24] . Some alleles, such as HLA-A2, maintain their expression despite low levels of TAP1-2 or tapasin [25, 26] , whereas others, such as HLA-B44, have strict requirements for certain antigen processing components [27] [28] [29] . These variations may explain the marked differences between HLA-A2 and HLA-B44 in the frequency of selective loss of expression in human tumors. HLA-A2 may be a "strong" allele able to maintain expression despite malignant transformation, whereas HLA-B44 may be a "weak" allele whose expression is often lost as a neoplasm develops. Differences in HLA class I allelic expression have been found in the presence of proteosome inhibitors [30] and in situations when invariant chain is expressed [31] . In this connection, alterations in HLA class I molecule expression can be considered an epiphenomenon of the process of malignant transformation, and thus as a marker of tumor clonality and immune selection [7, 8] .
Because different alleles can present different antigenic epitopes to cytotoxic T lymphocytes (CTLs) [32] , the selective loss of HLA class I alleles may have functional consequences, and may influence the interaction between CTLs and target cell. In cervical cancer, deficient HLA-B7 expression was associated with the development and progression of the neoplasm. Absence of the HLA-B7 molecule impeded presentation of the E6 oncoprotein derived from the human papillomavirus (HPV) [33] . In consonance with this finding, the HLA-B44 allele was found to predominate in cervical dysplasias, but its expression was lost when the lesion progressed to carcinoma. This loss may be sufficient to allow tumoral cells to escape immune surveillance, and may reflect the immunogenic importance of the HLA-B44 allele for the presentation of HPV epitopes to CTLs [34] . We also found that the HLA class I allele most frequently lost in three nonrelated human tumors (such as colorectal, laryngeal, and breast carcinomas) was the HLA B44 allele; consequently this finding must not be related with the presentation of HPV epitopes because colorectal and breast carcinoma are clearly not related with HPV infection, although laryngeal carcinoma may be [35] . No relation was found between HLA class I losses and the clinical and histopathologic parameters of the tumors, but the number of tumors we studied for each specific allele was very low.
Regardless of how HLA-B44 expression is lost in human tumors (i.e., via selective loss or loss of the HLA-B44 containing haplotype), it may be suggested that HLA-B44 presents an immunodominant peptide, the loss of which leads the host's immune system to tolerate the tumor. The HLA-B44 negative tumor variants may be selected through the antitumoral T-cell immune response against HLA-B44 positive tumor cells. Some studies have found evidence of immune selection of tumor cell variants that lose MHC class I expression in experimental and human tumors [7, 8, 36] , particularly after immunotherapy [37, 38] . This would further imply that other alleles such as HLA-A2, whose expression within the same tumor is maintained, present weakly immunogenic peptides. Tumor cell escape may occur as a result of maintenance, by antigen-presenting cells, of mainly HLA-B44 restricted CD8 lymphocytes that do not recognize HLA-B44 negative cells as targets [39] .
Defining the loss of expression of HLA class I alleles has significant potential benefits for selecting the best immunotherapeutic regimen to specifically stimulate antitumoral CD8 lymphocytes. Most tumor antigen peptides described to date are presented by HLA-A2, the most common allele in the Caucasoid population. Our findings suggest that this allele is rarely lost in colon, laryngeal, or breast tumors. Therefore it may have potential use in therapies for these tumors (assuming they are HLA-A2 positive) based on HLA-A2 restricted tumor peptides, and in the search for new tumor antigens presented by the HLA-A2 allele.
A variety of antigenic peptides able to stimulate antitumoral CD8 lymphocytes have been identified in recent years [40, 41] . Previous work has led to the isolation of several tumor antigens presented by HLA-B44 and other HLA molecules, such as MAGE-3 [42, 43] and the housekeeping gene MUM-2 [44] , respectively. A minor histocompatibility antigen specific for acute lymphoblastic leukemia has also been isolated [45] . Our findings suggest that patients with HLA-B44 typing who develop carcinomas of the colon, larynx, or breast are at high risk (71% versus 29%) for the loss of expression of this HLA class I allele.
